Exact2Pass
Last Update 16 hours ago Total Questions : 100
The Regulatory Affairs Certification (RAC) Global Scope content is now fully updated, with all current exam questions added 16 hours ago. Deciding to include RAC-GS practice exam questions in your study plan goes far beyond basic test preparation.
You'll find that our RAC-GS exam questions frequently feature detailed scenarios and practical problem-solving exercises that directly mirror industry challenges. Engaging with these RAC-GS sample sets allows you to effectively manage your time and pace yourself, giving you the ability to finish any Regulatory Affairs Certification (RAC) Global Scope practice test comfortably within the allotted time.
During a routine review of promotional materials for a product, a regulatory affairs professional discovers an off-label indication. Which of the following would be the FIRST follow-up action for the regulatory affairs professional to take?
Which of the following is NOT considered a serious adverse event in a cardiovascular clinical trial?
Company X encounters challenges in the global life cycle management of its medical devices. Which of the following Is MOST appropriate for improving product life cycle management?
One month prior to the anticipated approval date for your product, the marketing application that you submitted to a major regulatory authority has become the subject of an advisory committee meeting of experts convened by the regulatory authority. The advisory committee members unanimously vote not to approve your product because of a safety concern. Two days after the advisory committee meeting, the regulatory authority requests additional information to support the safety of your product. Assuming you have no additional data to provide, which of the following would be your MOST appropriate response to the regulatory authority ' s request?
During new drug development, a new impurity in the drug substance is detected at a level of 0.12%. The intended maximum daily dose Is less than 2 g/day, and the drug Is known generally not to be toxic.
What should be done in response to identifying the impurity?
A company is developing a new medical device using innovative technology. Which of the following is MOST critical in working with regulatory authorities?
The API used for an approved drug product conforms to international monograph specifications and local pharmacopeia; however, the international monograph specifications of the API will be changing soon. Which is the most appropriate action for the regulatory affairs professional to take FIRST?
